CA3136461A1 - Method of treating and preventing bone and joint infections - Google Patents

Method of treating and preventing bone and joint infections Download PDF

Info

Publication number
CA3136461A1
CA3136461A1 CA3136461A CA3136461A CA3136461A1 CA 3136461 A1 CA3136461 A1 CA 3136461A1 CA 3136461 A CA3136461 A CA 3136461A CA 3136461 A CA3136461 A CA 3136461A CA 3136461 A1 CA3136461 A1 CA 3136461A1
Authority
CA
Canada
Prior art keywords
lysin
seq
gram
bone
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136461A
Other languages
English (en)
French (fr)
Inventor
Raymond Schuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contrafect Corp
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of CA3136461A1 publication Critical patent/CA3136461A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3136461A 2019-04-11 2020-04-10 Method of treating and preventing bone and joint infections Pending CA3136461A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962832754P 2019-04-11 2019-04-11
US62/832,754 2019-04-11
US201962849672P 2019-05-17 2019-05-17
US62/849,672 2019-05-17
US201962938812P 2019-11-21 2019-11-21
US62/938,812 2019-11-21
US202062964755P 2020-01-23 2020-01-23
US62/964,755 2020-01-23
PCT/US2020/027752 WO2020210691A1 (en) 2019-04-11 2020-04-10 Method of treating and preventing bone and joint infections

Publications (1)

Publication Number Publication Date
CA3136461A1 true CA3136461A1 (en) 2020-10-15

Family

ID=72752118

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136461A Pending CA3136461A1 (en) 2019-04-11 2020-04-10 Method of treating and preventing bone and joint infections

Country Status (11)

Country Link
US (1) US20220193186A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980049A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022526624A (cg-RX-API-DMAC7.html)
KR (1) KR20210151188A (cg-RX-API-DMAC7.html)
CN (1) CN114025783A (cg-RX-API-DMAC7.html)
AU (1) AU2020271116A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019884A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136461A1 (cg-RX-API-DMAC7.html)
IL (1) IL286994A (cg-RX-API-DMAC7.html)
MX (1) MX2021012375A (cg-RX-API-DMAC7.html)
WO (1) WO2020210691A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081691A1 (en) * 2021-11-04 2023-05-11 Contrafect Corporation Method of treating and preventing bone and joint infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383544B (es) * 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
AU2013259512B2 (en) * 2012-05-09 2018-01-25 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
RU2646102C2 (ru) * 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
CN109152822B (zh) * 2016-05-12 2023-12-05 抗非特公司 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法
CN112118861A (zh) * 2018-02-26 2020-12-22 康特拉费克特公司 修饰的PlySs2溶素及其用途
MX2020013935A (es) * 2018-06-22 2021-03-09 Contrafect Corp Lisinas y sus derivados que resensibilizan staphylococcus aureus y bacterias gram positivas a antibioticos.

Also Published As

Publication number Publication date
WO2020210691A1 (en) 2020-10-15
AU2020271116A1 (en) 2021-11-11
MX2021012375A (es) 2021-11-17
IL286994A (en) 2021-12-01
US20220193186A1 (en) 2022-06-23
EP3980049A1 (en) 2022-04-13
KR20210151188A (ko) 2021-12-13
CN114025783A (zh) 2022-02-08
EP3980049A4 (en) 2023-07-19
JP2022526624A (ja) 2022-05-25
BR112021019884A2 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
US20250064902A1 (en) Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
JP6873939B2 (ja) バクテリオファージ溶解素によるバイオフィルムの防止、破壊および処置
JP6608697B2 (ja) グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
RU2234940C2 (ru) Способ лечения стафилококковых инфекций у млекопитающего (варианты)
NZ237202A (en) Composition containing beta-lactam antibiotic and cationic oligopeptide
JP2021527699A (ja) 溶解素及びその誘導体がスタフィロコッカス・アウレウス及びグラム陽性細菌を抗生物質に再感作する
JP2021513865A (ja) 修飾PlySs2溶解素及びその使用
US20220193186A1 (en) Method of treating and preventing bone and joint infections
US20220160842A1 (en) Method of treating infective endocarditis
WO2023081691A1 (en) Method of treating and preventing bone and joint infections
US10487117B2 (en) Antimicrobial peptide for nosocomial infections
WO2022261360A1 (en) Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾PlySs2溶解素及び抗生物質の組合せ
EP3724330A1 (en) Compositions and methods comprising lysin plycp025 and derivatives thereof

Legal Events

Date Code Title Description
B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20240722

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250925

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703